IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ZATTARIN, EMMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.394
EU - Europa 1.369
NA - Nord America 1.132
SA - Sud America 119
AF - Africa 39
OC - Oceania 7
Totale 4.060
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.088
DE - Germania 779
SG - Singapore 438
CN - Cina 379
IT - Italia 210
HK - Hong Kong 151
BD - Bangladesh 121
VN - Vietnam 114
BR - Brasile 97
IN - India 71
NL - Olanda 67
RU - Federazione Russa 63
FR - Francia 56
SE - Svezia 49
GB - Regno Unito 40
FI - Finlandia 37
CA - Canada 22
JP - Giappone 22
ID - Indonesia 21
CI - Costa d'Avorio 18
IE - Irlanda 18
TR - Turchia 14
KR - Corea 10
AT - Austria 9
AR - Argentina 8
PL - Polonia 8
CZ - Repubblica Ceca 6
MX - Messico 6
UA - Ucraina 6
IL - Israele 5
IQ - Iraq 5
NP - Nepal 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
CH - Svizzera 4
CO - Colombia 4
EG - Egitto 4
PH - Filippine 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
AU - Australia 3
BE - Belgio 3
DZ - Algeria 3
ES - Italia 3
JO - Giordania 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
EC - Ecuador 2
IR - Iran 2
LU - Lussemburgo 2
RO - Romania 2
SV - El Salvador 2
TW - Taiwan 2
VE - Venezuela 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CL - Cile 1
CU - Cuba 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MA - Marocco 1
MD - Moldavia 1
MR - Mauritania 1
MV - Maldive 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
TM - Turkmenistan 1
UY - Uruguay 1
VI - Stati Uniti Isole Vergini 1
Totale 4.060
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 716
Singapore 233
Ashburn 212
Hong Kong 132
San Jose 121
Dallas 86
Hefei 86
Chandler 74
Santa Clara 68
Council Bluffs 55
Beijing 51
Los Angeles 47
Milan 43
Bengaluru 35
Ho Chi Minh City 34
Boardman 32
New York 28
Munich 25
Hanoi 24
Lauterbourg 23
Helsinki 21
Guangzhou 20
Buffalo 19
Moscow 19
Abidjan 18
Dublin 18
Nuremberg 14
Jakarta 13
Tokyo 13
Cangzhou 12
Chicago 12
Hyderabad 10
Phoenix 10
Princeton 10
Turin 10
London 9
Rome 9
Dong Ket 8
Seoul 8
Shanghai 8
Southend 8
Turku 8
Istanbul 7
Lappeenranta 7
Montreal 7
Rho 7
Salt Lake City 7
São Paulo 7
Amsterdam 6
Naples 6
Shenzhen 6
Wilmington 6
Atlanta 5
Biên Hòa 5
Düsseldorf 5
Tashkent 5
Thái Nguyên 5
Vienna 5
Warsaw 5
Berlin 4
Cagliari 4
Cambridge 4
Chennai 4
Da Nang 4
Dhaka 4
Eitensheim 4
Elk Grove Village 4
Florence 4
Johannesburg 4
Manchester 4
McAllen 4
Nanjing 4
Paris 4
Salvador 4
Seattle 4
Tel Aviv 4
Voghera 4
Washington 4
Zurich 4
Amman 3
Auckland 3
Bexley 3
Brantford 3
Brescia 3
Brussels 3
Cairo 3
Curitiba 3
Denver 3
Fortaleza 3
Fuzhou 3
Haiphong 3
Hangzhou 3
Juiz de Fora 3
Kathmandu 3
Lahore 3
Medford 3
Olomouc 3
Osaka 3
Padua 3
Perugia 3
Totale 2.646
Salva come PNG Salva come JPEG
Nome #
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 253
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 250
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 238
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 226
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 222
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 199
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 194
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 193
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 184
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 181
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 178
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 174
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 172
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 164
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report 163
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis 138
“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.” 127
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer 124
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis 122
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis 116
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications 107
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications 107
Gender-Based Differences in the Efficacy of Anti-EGFR/BRAF/MEK Targeted Therapy in Patients with BRAF-Mutated Metastatic Colorectal Cancer 105
Fasting-mimicking diet plus chemotherapy in breast cancer treatment 72
Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer 67
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis 61
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer 15
null 3
PARPi effectiveness after CDK4/6i in BRCA1- and BRCA2-associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study 2
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 4.158
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.790
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 0 9
2021/202265 0 3 2 1 4 2 1 8 2 1 16 25
2022/2023247 23 25 18 18 24 45 5 23 32 4 29 1
2023/2024649 11 10 14 13 44 35 111 82 40 88 104 97
2024/20251.081 84 99 92 96 50 30 55 65 67 124 95 224
2025/20262.104 231 211 242 155 141 86 259 60 193 147 197 182
Totale 4.158